Tougher trial for Antisoma drug
US regulators have set tougher approval requirements for Antisoma's lead cancer treatment drug, delaying launch of the medicine by at least two years and increasing the likelihood it will never be
US regulators have set tougher approval requirements for Antisoma's lead cancer treatment drug, delaying launch of the medicine by at least two years and increasing the likelihood it will never be